$IOVA

Iovance Biotherapeutics (IOVA) reported a 50% response rate in a trial of its lifileucel therapy for metastatic sarcoma, with four ongoing partial responses. The trial involved eight patients with prior treatments, and the safety profile matched other indications. The FDA granted fast track designation for lifileucel in Q2 2026. Iovance is conducting a Phase 2 trial with a primary endpoint of objective response rate.

Iovance Biotherapeutics reported phase 2 data showing a 62.5% objective response rate and 29.2% complete response rate for Amtagvi combined with Merck's Keytruda in first-line melanoma patients. The data was presented at a medical conference.

Iovance reported Phase 2 data showing 62.5% ORR and 29.2% CR for lifileucel plus pembrolizumab in frontline advanced melanoma. Median OS not reached at 50.9 months' follow-up. The results support a potential shift to frontline use, aligning with Phase 3 strategy.

Iovance Biotherapeutics (IOVA) granted 111,615 stock options to 21 new employees under its 2021 Inducement Plan. Each option has an exercise price of $14.72 and vests over three years. The company focuses on developing TIL therapies for cancer patients.

Iovance Biotherapeutics [IOVA] reported Q2 2026 revenue of $99.3m, raising full-year guidance to $410m-$420m. Its FDA-approved TIL therapy, Amtagvi, faces logistical challenges but shows commercial momentum. IOVA stock surged 28% post-guidance upgrade, up 433% YTD. Competitors include Immunocore [IMCR] and Bristol-Myers Squibb [BMY].

Iovance Biotherapeutics (IOVA) announced progress in its Phase 2 SARATOGA study, testing lifileucel for advanced soft tissue sarcoma. The trial, with no placebo, aims to evaluate the therapy's efficacy and safety. The study is actively recruiting, suggesting timeline adherence. Positive results could expand lifileucel's market beyond melanoma, according to the company.

Iovance Biotherapeutics (IOVA) shares rose 9.84% after raising its 2026 revenue outlook to $410M-$420M, driven by strong demand for cancer drugs Amtagvi and Proleukin. Analysts upgraded price targets, citing the company's leading position in tumor-infiltrating lymphocyte therapies. Despite losses, investors are optimistic about commercial growth and improving margins.

Iovance Biotherapeutics updated its corporate presentation, affirming 2026 revenue guidance of $410M–$420M, up ~15% from prior estimates. The company reported 2Q26 revenue of ~$99M, a 66% YoY increase for Amtagvi, with ~$304M in cash as of 6/30/26 and a 56% gross margin. It has ~100 Authorized Treatment Centers and capacity for 5K annual patients.

IOVANCE BIOTHERAPEUTICS, INC. (IOVA) filed an SEC Form 8-K — Other Events. Exhibit 99.1 1 © 2026, Iovance Biotherapeutics, Inc. © 2026, Iovance Biotherapeutics, Inc. Corporate Overview October 2026 1 2 © 2026, Iovance Biotherapeutics, Inc. Forward - Looking Statements Certain matters discussed in this presentation are “forward - looking statements” of I

Several biotech stocks hit 52-week highs on September 29, 2026. Iovance (IOVA) rose 31% to $11.17, raising its revenue guidance to $410M-$420M. Xeris (XERS) reached $11.33, with updates on its XP-8121 program. AbCellera (ABCL) peaked at $14.82, with positive Phase 2 results for ABCL635. Grail (GRAL) hit $140.88 after FDA panel support for its Galieri test. Sight Sciences (SGHT) climbed to $9.71, reporting $23M in Q2 revenue, up 20% YoY.